388 related articles for article (PubMed ID: 36654819)
1. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.
Barreca M; Lang N; Tarantelli C; Spriano F; Barraja P; Bertoni F
Explor Target Antitumor Ther; 2022; 3(6):763-794. PubMed ID: 36654819
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.
Riccardi F; Dal Bo M; Macor P; Toffoli G
Front Pharmacol; 2023; 14():1274088. PubMed ID: 37790810
[TBL] [Abstract][Full Text] [Related]
3. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.
Sganga S; Riondino S; Iannantuono GM; Rosenfeld R; Roselli M; Torino F
J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763107
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.
Gogia P; Ashraf H; Bhasin S; Xu Y
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568702
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
Peng H
Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
[TBL] [Abstract][Full Text] [Related]
10. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
[TBL] [Abstract][Full Text] [Related]
11. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Antibody Drug Conjugates for Lymphoma.
Russler-Germain DA; Kahl BS
Oncology (Williston Park); 2020 Dec; 34(12):522-534. PubMed ID: 33395492
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
14. Introduction to Antibody-Drug Conjugates.
Pettinato MC
Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
[TBL] [Abstract][Full Text] [Related]
16. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
17. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
19. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
Nguyen TD; Bordeau BM; Balthasar JP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
